Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Auspex Pharmaceuticals Inc announces data from interim analysis of ARC-HD switch trial demonstrating clinical activity of SD-809


Monday, 23 Jun 2014 04:40pm EDT 

Auspex Pharmaceuticals Inc:Says results from a pre-specified interim subgroup analysis of ongoing open-label ARC-HD Switch study in which the clinical experience of switching subjects' treatment from tetrabenazine to SD-809 was evaluated.Interim analysis was conducted to determine whether chorea control was maintained after converting subjects with Huntington's disease (HD) from stable doses of tetrabenazine to SD-809, which is administered in lower doses and with a simplified dosing regimen.In accordance with the pre-specified interim analysis plan, 12 subjects were included in the subgroup analysis, all of which had chorea assessed one week after switching from tetrabenazine to SD-809 and eight of which had chorea assessed four weeks after switching.At one and four weeks after switching to SD-809, the mean total chorea score decreased by about one point from baseline, indicating that SD-809 maintained chorea control in these subjects.Conversion to SD-809 was generally well tolerated as no subject prematurely discontinued from the study, there were no adverse events of loss of chorea control and no serious adverse events were reported. 

Company Quote

100.95
0.06 +0.06%
1 May 2015